Clinical Application Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 as Indicators of Inflammation Persistence and Acute Kidney Injury in Children with Urinary Tract Infection by Petrović, Stanislava et al.
Hindawi Publishing Corporation
BioMed Research International
Volume 2013, Article ID 947157, 9 pages
http://dx.doi.org/10.1155/2013/947157
Clinical Study
Clinical Application Neutrophil Gelatinase-Associated Lipocalin
and Kidney Injury Molecule-1 as Indicators of Inflammation
Persistence and Acute Kidney Injury in Children with Urinary
Tract Infection
Stanislava Petrovic,1 Natasa Bogavac-Stanojevic,1 Amira Peco-Antic,2,3 Ivana Ivanisevic,2
Jelena Kotur-Stevuljevic,1 Dusan Paripovic,3 Miron Sopic,1 and Zorana Jelic-Ivanovic1
1 Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, P.O. Box 146, 11000 Belgrade, Serbia
2 School of Medicine, University of Belgrade, 11000 Belgrade, Serbia
3 Department of Nephrology, University Children’s Hospital, 11000 Belgrade, Serbia
Correspondence should be addressed to Natasa Bogavac-Stanojevic; naca@pharmacy.bg.ac.rs
Received 8 April 2013; Revised 10 June 2013; Accepted 14 June 2013
Academic Editor: Vickram Ramkumar
Copyright © 2013 Stanislava Petrovic et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background. The aim of this study was to examine the novel renal biomarkers neutrophil gelatinase-associated lipocalin (NGAL)
and kidney injurymolecule-1 (KIM-1) to assist pediatricians in the assessment of longer duration of inflammation and acute kidney
injury (AKI) development during urinary tract infection (UTI).Methods. The patients enrolled in the study comprised 50 children
(mean age was 6 months) with UTI. NGAL in serum and urine (sNGAL and uNGAL, resp.) and KIM-1 in urine were measured
by enzyme-linked immunosorbent assays. Results. uNGAL levels in subjects with longer duration of inflammation were higher
(115.37 ng/mL) than uNGAL levels in subjects with shorter duration of inflammation (67.87 ng/mL, 𝑃 = 0.022). Difference in
sNGAL and KIM-1 levels was not significant (𝑃 = 0.155 and 𝑃 = 0.198, resp.). Significant difference was seen in KIM-1 excretion
among groups with and without AKI (𝑃 = 0.038). KIM-1 was not able to discriminate between subjects with and without AKI (area
under the curves (AUC) = 0.620, 𝑃 = 0.175). Conclusions. uNGAL cannot be used for screening of the duration of inflammation
during UTI. Accuracy of KIM-1 in screening of AKI development in children with UTI is low. We suggest larger studies to check
the negative predictive value of KIM-1 for the development of AKI.
1. Introduction
Urinary tract infection (UTI) is one of the most com-
mon infectious diseases encountered by pediatric healthcare
providers [1]. Early diagnosis and treatment of UTI are
important, because missed or delayed diagnosis of UTI may
result in the failure of appropriate treatment and possibly
lead to long-term consequences, including renal scarring,
hypertension, and chronic renal failure [2]. More severe
forms of UTI may also cause acute complications. Children
with UTI may develop a prerenal type of acute kidney
injury (AKI) as a result of renal hypoperfusion due to severe
dehydration.The cause of AKI in children with UTI may also
be of a renal origin, but significantly lower. In any case, AKI
should be discovered as soon as possible to start the therapy
and prevent the progression and consequences (permanent
damage to the kidneys).
The incidence of AKI in pediatrics is significant, and
despite alarming data, therapeutic interventions have failed
to effect a meaningful difference in outcomes [3]. At 3–5
years follow up, 40%–50% of pediatric patients who suffered
AKI show signs of chronic renal insufficiency, indicating
that sublethal injury permanently alters the renal bed [4].
Timely identification of children with AKI may be critical to
management, though current laboratory and clinical markers
may be unreliable for acute injury [3]. Several-fold changes in
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serum creatinine or creatinine clearance are the main criteria
that have been used to diagnose AKI. However, changes in
serum creatinine values lag behind the degree of injury to
the renal tubular epithelial cells [3]. The search is on for real-
timemarkers ofAKI, whichwould allow for rapid and reliable
diagnosis. A good AKI biomarker should be noninvasive,
easily obtainable, and measurable using standardized assays
with fast results and reasonable cost to perform [5]. Also,
it is important to state that they change only because of
kidney damage and not due to infection, inflammation,
and other causes. Recently, several biomarkers have been
explored for the early diagnosis of AKI, including cystatin
C, interleukin-18 (IL-18), neutrophil gelatinase-associated
lipocalin (NGAL), and kidney injurymolecule-1 (KIM-1) [6].
Cystatin C is a cysteine protease inhibitor that is synthe-
sized and released into the blood at a relatively constant rate
by all nucleated cells, freely filtered by the glomerulus, com-
pletely reabsorbed by the proximal tubule, and not secreted
[7]. In a number of baseline pediatric studies, serum cystatin
C levels were diagnostically superior to serum creatinine
and were independent of gender, body composition, or
muscle mass [8]. However, clinicians should be cognizant of
extrarenal conditions and pharmacological factors that can
influence the results of serum cystatin C assays.
IL-18 is a proinflammatory cytokine that is induced
and cleaved in the proximal tubule and subsequently easily
detected in the urine following ischemic AKI [9]. Peak urine
IL-18 concentration increases with worsening AKI severity in
critically ill children but performs poorly as an early predictor
of AKI [10]. Further studies will hopefully elucidate which
patients and in what clinical settings an inflammatorymarker
such as IL-18 can be useful for early AKI prediction [5].
NGAL is a novel protein identified in human neutrophil
granules and is considered to be a component of the innate
immune system, highly involved in several cellular responses,
including bacteriostasis, cell proliferation and differentiation,
and apoptosis [11, 12]. NGAL is a 25 kDa lipocalin secreted
by activated neutrophils, expressed in many cells, and is
upregulated in several injury settings including infection,
cancer and renal tubular injury [5]. Urine and plasma
NGAL measurements represent early biomarkers of AKI in
a heterogeneous pediatric intensive care setting, being able
to predict this complication about 1-2 days prior to the rise
in serum creatinine with high sensitivity [13, 14]. Therefore,
NGAL has good features as a marker of renal function, but it
is also a marker of inflammation so that the diagnosis of AKI
is not applicable for all pathological conditions.
KIM-1 has been examined lately as a marker of kidney
function, as well as its stability in different clinical conditions.
KIM-1 is a type-1 transmembrane glycoprotein expressed in
low levels of the normal kidney, which is highly upregulated
in the proximal tubules after ischemic or toxic AKI [5].
With renal tubular injury, the extracellular domain of KIM-
1 is cleaved from the transmembrane domain by proteolytic
enzymes and released into the urine [15–17]. KIM-1 mediates
epithelial phagocytosis in the injured kidney converting the
proximal epithelial cell into a phagocyte, with potentially
important pathophysiological implications for modulation of
the immune response and repair process after injury [18].
However, none of these markers have been systematically
evaluated in various clinical settings of AKI [19]. Further-
more, it is unlikely that a single biomarker will consistently
provide sufficient precision to detect AKI early in all clinical
situations; a combination of biomarkers could provide disease
specific patterns or increased precision [20]. In our study,
we examined the changes in parameters of renal function:
KIM-1, urine, and serum level of NGAL (uNGAL and
sNGAL, resp.) in relation to infection and in relation to the
development of AKI. We also investigated the diagnostic
ability to screen AKI development and longer duration of
inflammation in children with UTI.
2. Patients and Methods
We performed a prospective single-center study of children
with UTI at the University Children’s Hospital in Belgrade,
Serbia, over a period of one year. Fifty patients with first
febrile UTI action at admission to the hospital were enrolled
in this study. An informed consent of parents was obtained
prior to enrolling children into the study, which was planned
according to ethical guidelines following the Declaration of
Helsinki. The institutional review committee approved our
study protocol thereby following local biomedical research
regulations. Children with known urogenital or anorectal
malformations or neurological disease were excluded. Inves-
tigations, treatment, and furthermanagementwere according
to the hospital guidelines. After obtaining informed consent
at the time of admission to the hospital, urine culture,
urinalysis, serum urea, creatinine (Cr), C-reactive protein
(CRP), and white blood cell (WBC) count measurements
were performed. Patients whomet the following criteria were
included in the study: fever higher than 38.5∘C with no other
recognizable cause, leukocytosis defined as leukocyte count
more than the normal value according to age, CRP higher
than 20mg/L, positive dipstick for leukocyte esterase, and/or
pyuria (urine specimen with ≥10 WBC). Urine samples
were obtained by midstream clean catch or sterile bags,
and UTI was diagnosed if there was significant bacteriuria
(>100.000 colony-forming units (CFU/mL)) in the urine
culture. Urine samples were obtained in hospital by health
care personnel, and the collection of data as well as laboratory
methods were consistent through the study period. All
children underwent abdominal and urinary tract ultrasound
examination within 48 h of admission to the hospital while
voiding cystourethrography (VCUG) was optional, at the
treating physician’s request and parents’ decision. For all
patients, repeat urine, urine culture, blood WBC, and CRP
were performed after 48–72 h of admission to the hospital.
Discharge criteria were evaluated by analyzing the clinical
response to the antibiotics therapy (fever, blood WBC and
CRP, urine WBC, and urine culture).
The classification of patients was carried out in two
ways: assessment of renal function and of the duration of
inflammation at UTI according to the CRP value at discharge
from hospital. Assessment of renal function was performed
via estimated GFR using the Schwartz formula [21].The divi-
sion of patients into groups according to AKI development
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(with AKI and without AKI, resp.) was performed according
to the decline of GFR to below 25% in relation with the
normal values for age [22]. In another classification, patients
were divided according to CRP value at discharge from the
hospital. CRP is a direct and quantitative marker of the acute
phase reaction, and the severity of inflammation at UTI,
as measured by serum CRP, is significantly associated with
permanent renal damage. A level of CRP ≥10mg/L is con-
sidered to be indicative of a clinically-relevant inflammatory
condition [23], while high levels of CRP mean prolonged
inflammation that can lead to the development of fibrosis and
scar formation in the kidney. Accordingly, two groups were
formed: patients with CRP levels higher than 10mg/L were
marked as patients with a longer duration of inflammation
(coded with 1), while patients with CRP levels less than
10mg/L were marked as patients with a shorter duration of
inflammation (coded with 0).
Blood and urine samples were drawn from each patient to
measure the following parameters: serum concentrations of
NGAL, Cr, urea andCRP, urine concentrations ofNGAL, and
KIM-1. The urine samples were immediately centrifuged at
4∘C for 15min at 13,000 g. Samples were frozen at −80∘C and
analysed within 3 months. Cr and urea levels were analyzed
by routine methods (Olympus System Reagents using an
Olympus analyser AU 2700, Hamburg, Germany). CRP was
determined by a nephelometric method (Siemens C-reactive
protein assay using a Dimension RxL Max Integrated Chem-
istry System, Erlangen, Germany). sNGAL, uNGAL, and
KIM-1 were measured by enzyme-linked immunosorbent
assays (ELISAs) using polyclonal goat antibodies against
human proteins coated onto the wells of microtitre plates
(R&D Systems Europe, Abingdon, United Kingdom). Urine
samples were diluted 1 : 60 for uNGAL, while serum samples
for sNGAL were diluted 1 : 40. Urine samples for KIM-1
were not diluted. NGAL and KIM-1 levels were expressed as
nanograms per milliliter.
Statistical analyses were made with MedCalc for Win-
dows Version 9.6.3. (Mariakerke, Belgium) statistical soft-
ware.The distributions of variables were checked for normal-
ity, and logarithmic transformationwas used for skewed data.
Interindividual and intraindividual variation was calculated
in groups of subjects formed according to ages.The coefficient
of variation (CV) between subjects (interindividual varia-
tion) for each parameter was calculated at the time of admis-
sion to the hospital and at the time of hospital discharge.
Intraindividual variation was expressed as the correlation
between the value measured by each subject at the time of
admission to the hospital and value of the same parameter
at the time of hospital discharge, by calculating Spearman’s
correlation coefficient. Differences between subjects at the
time of admission to the hospital and at the time of hospital
discharge (two points of measurement) were analyzed with a
paired Student 𝑡-test.The effects of inflammation and AKI on
serum and urinary variables at the time of hospital discharge
were compared by analysis of covariance (ANCOVA) with
adjustment for baseline levels (values at the time of admission
to the hospital). Additionally, change in examined variables
was analysed using repeated-measures analysis of variance
(ANOVA) with “time” as within and the “presence of AKI”
as between factors. Accuracy of the examined parameters was
assessed using receiving operative characteristic (ROC) curve
analysis. Parameterswith significant accuracywere combined
with other parameters, and curves for these models were
plotted, and areas under the curves (AUCs) were presented
as C statistics from the analysis. Data are shown as mean
± standard deviation for normally-distributed continuous
variables and as relative of absolute frequencies for categorical
variables. Logarithmic-transformed variables were expressed
as geometrical mean and 95% confidence interval (CI) for the
mean. All tests were considered significant at 𝑃 < 0.05.
3. Results
The patients enrolled in the study comprised 50 Caucasian
children from 1 month to 12 years of age with first-time
community-acquired UTI, of whom 28 were male and 22
were females. Eighty-six percent of children were younger
than 12months, 8%were from 12months to 36months of age,
and 6% were older than 36 months. As might be presumed,
in most cases the cause of UTI was Escherichia coli (88%,
44 cases). The average hospital length of stay was 5.5 days.
Baseline characteristics of the study population are presented
in Table 1.
Because the age of the children was from 1 month to 12
years, inter- and intraindividual variability in each measured
parameter was calculated at the time of admission to the
hospital and at the time of hospital discharge, separately in
the groups of children younger and older than 12 months.
Interindividual variability was presented in Figure 1. In
groups of older children, CVs for all parameters (except
for sNGAL at the time of admission to the hospital) were
lower than CVs in groups of younger children. Likewise, CVs
were higher in all groups at the time of hospital discharge
than at the time of admission to the hospital (except for
sNGAL in group of older children). Correlation coefficients
(intraindividual variability) for each parameter in younger
and older subjects when measured at the time of admission
to the hospital and at the time of hospital discharge were
significant for uNGAL in younger subjects (𝑟 = 0.736, 𝑃 <
0.001) and for sNGAL in older subjects (𝑟 = 0.786, 𝑃 =
0.036). The agreement between values measured at the time
of admission to the hospital and at the time of hospital dis-
charge for other parameters was lower and without statistical
significance.There was no difference in examined parameters
(uNGAL, sNGAL, and KIM-1) between children younger
than 12 months and children older than 12 months (data not
shown).
Renal biomarkers and inflammatory parameters of sub-
jects at the time of admission to the hospital and at the time
of hospital discharge are listed in Table 2. The levels of all
parameters were significantly higher at the time of admission
to the hospital than corresponding values at the time of
hospital discharge.
Effects of infection (expressed in relation to the concen-
tration of CRP) on levels of renal parameters are presented
in Table 3. Adjusting by ANCOVA for values at the time of
admission to the hospital, uNGAL levels in subjects with
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Age (months)∗ 6.00 (4.00–7.00) 3.3 (2.37–4.40) 11.7 (7.07–18.12)
Gender, male (%) 56 61.5 38.5
BMI (kg/m2) 11.67 ± 4.29 10.36 ± 2.02 12.88 ± 5.69a
Fever (∘C) 39.22 ± 0.658 39.17 ± 0.58 39.22 ± 0.77
Duration of fever (days) 3.1 ± 1.45 2.74 ± 1.29 3.75 ± 1.52a
Duration in hospital (days)∗ 5.46 (5.00–6.00) 5.41 (4.24–6.90) 5.89 (5.21–7.61)
GFR (mL/min/m2) 49.20 ± 13.34 51.13 ± 10.07 40.42 ± 12.49
sCr (𝜇mol/L) 57.85 ± 13.99 50.70 ± 7.56 65.40 ± 15.60
Urea (mmol/L)∗ 2.87 (2.50–3.31) 2.47 (2.06–2.98) 3.40 (2.61–4.42)a
Leukocyte number (×10e9/L) 17.55 ± 5.92 16.38 ± 5.16 19.12 ± 6.5a
Urine culture (%)
Escherichia coli 88 90.9 85.0
Klebsiella 4.8 4.5 5
Proteus 4.8 0 10
Other 2.4 4.5 0
Therapy (%)
Longaceph (ceftriaxone) 38.6 39.1 38.1
Amikacin 36.4 30.4 42.9
Combination 25.0 30.5 19.0
Data are mean ± SD, percentages, or ∗geometrical mean (95% CI for the mean) for variables with skewed distribution. asignificantly different from group
without AKI by Student t-test.
120.00
100.00






Younger than 12 months





Figure 1: Interindividual variability: comparison of coefficient of variation for uNGAL, sNGAL and KIM-1 in younger and older subjects at
the time of admission to the hospital and at the time of hospital discharge.
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Table 2: Renal biomarkers and inflammatory parameters of 50
subjects at the time of admission to the hospital and at the time of
hospital discharge.
Hospital admission Hospital discharge P
sNGAL, ng/mL 153.90 ± 75.04 91.34 ± 56.63 <0.001
uNGAL, ng/mL 155.00 ± 92.39 94.03 ± 76.76 <0.001
KIM-1, ng/mL 0.38 (0.28–0.50) 0.24 (0.17–0.34) 0.037
CRP, mg/L 72.62 (54.38–96.96) 13.12 (9.71–17.72) <0.001
Data aremean± SD or geometrical mean (95%CI for themean) for variables
with skewed distribution.
Serum level of neutrophil gelatinase-associated lipocalin (sNGAL), urine
level of neutrophil gelatinase-associated lipocalin (uNGAL), urine level of
kidney injury molecule-1 (KIM-1), and serum level of C-reactive protein
(CRP).
Table 3: Effects of infection on renal parameter levels at the time
of hospital discharge when values at the time of admission to the








sNGAL, ng/mL 78.80 ± 14.68 104.82 ± 10.17 0.155
uNGAL, ng/mL 67.87 ± 16.04 115.37 ± 11.72 0.022a
KIM-1, ng/mL 0.169 (0.08–0.34) 0.295 (0.182–0.479) 0.198
Data are adjustedmean ± SD or geometrical mean (95%CI for the mean) for
variables with skewed distribution. asignificant differences between groups
in ANCOVA with adjustment for baseline values.
Shorter duration of inflammation—CRP level less than 10mg/L at the time of
hospital discharge, longer duration of inflammation—CRP level higher than
10mg/L at the time of hospital discharge.
longer duration of inflammation were higher (115.37 ng/mL)
than uNGAL levels in subjects with shorter duration of
inflammation at the same time (67.87 ng/mL, 𝑃 = 0.022).
After inclusion of ages as additional covariate difference in
uNGAL values between groups was significant, 𝑃 = 0.031.
sNGAL and urinary KIM-1 levels showed not significant (𝑃 =
0.155 and 𝑃 = 0.198, resp.) trends towards increases in the
group with longer duration of inflammation compared with
the group with shorter duration of inflammation.
The ability of renal parameters to detect longer duration
of inflammation was investigated by ROC curve analysis.
Urinary KIM-1 (AUC = 0.519, 𝑃 = 0.847), uNGAL (AUC
= 0.549, 𝑃 = 0.638), sNGAL (AUC = 0.516, 𝑃 = 0.855), Cr
(AUC=0.538,𝑃 = 0.695), and urea (AUC=0.560,𝑃 = 0.538)
at the time of admission to the hospital were not able to
detect longer duration of inflammation. Of the parameters we
examined, only a number of leukocytes significantly detected
longer duration of inflammation (AUC = 0.688, 𝑃 = 0.047),
(Figure 2(a)). We also investigated the potential benefit of
adding renal parameters to a number of leukocytes to better
discriminate subjects with longer duration of inflammation
from subjects with shorter duration of inflammation. The
addition of Cr and urea increased the AUC for number of
leukocytes (AUC = 0.723, 𝑃 = 0.027 (Figure 2(a)) and AUC
= 0.762, 𝑃 = 0.009 (Figure 2(b)), resp.), whereas the addition
of uNGAL had a marginal effect (AUC = 0.695, 𝑃 = 0.041),
(Figure 2(b)).
Time-related changes in urinary KIM-1 excretion differed
significantly among two points of measurement (at the time
of hospital admission and at the time of hospital discharge),
and a similar significant difference was seen in urinary KIM-
1 excretion among groups with AKI and without AKI (AKI
groups: 𝑃 = 0.038; time: 𝑃 = 0.037; AKI group × time: 𝑃 =
0.971; repeated-measures ANOVA, Figure 3).
The ability of KIM-1 to detect AKI development was
investigated by ROC curve analysis. Urinary KIM-1 at the
time of subject admission to hospital (AUC = 0.620, 𝑃 =
0.175) was not able to discriminate between subjects with
AKI and without AKI. On the other hand, the AUC for urea
was higher (AUC = 0.681, 𝑃 = 0.040). A combination of
KIM-1 with urea increased the ability of urea to discrim-
inate impaired risk for AKI (AUC = 0.705, 𝑃 = 0.023),
(Figure 2(c)).
4. Discussion
All recent pediatric AKI studies demonstrate that AKI results
more often as a sequel to another systemic illness or its
treatment [24, 25], and not from primary kidney disease
itself [20]. A possible cause for the development of AKI
is a severe form of UTI. Late AKI diagnosis and delay in
supportive therapy may result in increased mortality. This
is supported by the observation that even small increases
in Cr (50% or 0.3mg/dL) are independently associated with
patient mortality [26–28]. It is clear that while the RIFLE
(risk, injury, failure, loss, end-stage kidney disease) [27] and
AKIN (acute kidney injury network) [29] strata are helpful
for retrospective reviews and epidemiological study, they
have limited utility to the clinician evaluating a child in real-
time [3]. On the other hand, current diagnostic procedure for
monitoring renal involvement during UTI (upper UTI) and
related parenchymal inflammation is scintigraphy. This is an
invasive and expensive technique that is not always available,
and a search for noninvasive methods is therefore relevant
[30]. Substantial research has been carried out over the past
decade to discover and validate biomarkers to detect AKI
before a rise in Cr in hospitalized patients [20].
Taking into account the data above, the aim of this study
was to examine the novel renal biomarkers NGAL and KIM-1
to assist pediatricians in the assessment of longer duration of
inflammation and developing AKI during UTI. However, the
first step was to examine the stability of examined parameters
in infection. The levels of uNGAL were significantly higher
at the time of admission to the hospital than corresponding
values at the time of hospital discharge, as well in subjects
with longer duration of inflammation than in subjects with
shorter duration of inflammation; so our results confirmed
that uNGAL is sensitive to the state of infection.
According to the literature, both uNGAL and uNGAL/Cr
can be used as sensitive markers for early prediction of UTI
in the absence of AKI and chronic kidney disease [1]. NGAL
is released by activated neutrophils of the infected host and
prevents bacterial iron uptake consuming the ambient iron


















































Figure 2: ROC curves for parameters with significant diagnostic ability for duration of inflammation and significant diagnostic ability for
AKI. (a): ROC curves for a number of leukocytes and for a combination of leukocyteswithCr for detection of longer duration of inflammation;
(b): ROC curves for a combination of leukocytes with urea or uNGAL for detection of longer duration of inflammation; (c): ROC curves for
parameters with significant discriminative abilities for AKI (KIM-1, urea, combination of KIM-1 and urea).











AKI groups: P = 0.038; time: P = 0.037
Without AKI
Admission to the hospital Hospital discharge
With AKI
Figure 3: Urinary KIM-1 levels at the time of subject admission to
the hospital and at the time of hospital discharge among groups with
AKI and without AKI. In the figure, there are presented means and
standard error values.
and thus reducing bacterial growth [7, 31]. Expression of
NGAL increases as part of the immune response to remove
bacteria in the early stage of infection [1]. Also, uNGAL
is increased in AKI induced by nephrotoxins or ischemia,
probably because NGAL expression is induced to contribute
to tissue regeneration after kidney damage [32, 33]. However,
in this case, NGAL measurements may be influenced by a
number of coexisting variables, such as pre-existing renal dis-
ease [34] and systematic or urinary tract infections [35, 36].
In addition, we tested whether uNGAL could be a reliable
marker for discrimination between longer and shorter dura-
tion of inflammation in the assessment of disease severity.
Of the parameters KIM-1, uNGAL, sNGAL, Cr, and urea,
only the number of leukocytes significantly detected a longer
duration of inflammation (AUC = 0.688, 𝑃 = 0.047). We also
investigated the potential benefit of adding renal parameters
to the number of leukocytes to better discriminate subjects
with longer duration of inflammation.The addition of Cr and
urea increased the AUC for a number of leukocytes (AUC =
0.723, 𝑃 = 0.027 and AUC = 0.762, 𝑃 = 0.009, resp.), whereas
the addition of uNGAL had a marginal effect (AUC = 0.695,
𝑃 = 0.041), (Figures 2(a) and 2(b)). The baseline value of
uNGAL was not able to discriminate between children who
will have a longer duration of inflammation than children
with a shorter duration of inflammation.
Although the levels of KIM-1 were higher at the time
of admission to the hospital than corresponding values at
the time of hospital discharge, KIM-1 showed no signif-
icant trends towards increases in the group with longer
duration of inflammation compared with the group with
shorter duration of inflammation. Herein is reviewed the
diagnostic and prognostic performance of several types of
urinary biomarkers for the diagnosis and risk stratification
of AKI, where KIM-1 was not classified in the group of
inflammatory markers for the diagnosis of AKI, in contrast
to NGAL and IL-18 [37]. For now, it is well known that KIM-
1 expression is elevated in various etiologies of AKI, chronic
kidney disease, the kidney transplant population, and renal
cell carcinoma [38]. Previous studies have shown that the
normalized urinary KIM-1 levels were significantly higher
in patients with ischemic acute tubular necrosis compared
to levels in patients with other forms of acute renal failure
or chronic renal disease [16], and in patients with AKI
than in patients with UTI [19]. Existing studies have been
insufficiently powered to establish a cut-off value that is
predictive of AKI [38]. Furthermore, it is unclear whether
expression of KIM-1 is related to the pathogenesis of the
injury itself ormarker of attempted recovery and repair. KIM-
1 is unique in being the first molecule that transforms kidney
proximal epithelial cells into semiprofessional phagocytes
[39]. As a consequence of its role in enhancing the clearance
of dead cells by the surviving tubular cells, KIM-1 may act
to modulate immune response in AKI, and phagocytosis
of apoptotic cells may downregulate the proinflammatory
immune response [18].
We tested the hypothesis that urinary excretion of KIM-1
is increased in children with UTI, related to renal damage.
We wanted to investigate the ability of this protein as a
potential biomarker for the diagnosis of AKI in the presence
of UTI. Our study showed significant difference in urinary
KIM-1 excretion among groups with AKI and without AKI
(Figure 3), but urinary KIM-1 at the time of hospital admis-
sionwas not able to discriminate between these two groups of
patients (AUC= 0.620,𝑃 = 0.175).The discrimination ability
of KIM-1 for AKI was less than the traditional parameter urea
(AUC = 0.681, 𝑃 = 0.040). A combination of KIM-1 with urea
increased the ability of urea to discriminate impaired risk for
AKI (AUC = 0.705, 𝑃 = 0.023), (Figure 2(c)).
The published clinical studies of urine KIM-1 are small so
far, and there is no clear evidence whether urinary KIM-1 is
an effective AKI diagnostic test in humans [38]. Early studies
of adults suggest that KIM-1 appears to discriminate patients
with different types of acute tubular necrosis (hospitalized
patients, critically ill patients, patients with acute graft rejec-
tion) from those without AKI [19, 40]. To our knowledge, this
is the first study where KIM-1 is considered as a biomarker
for prediction of AKI in children with UTI.The first reported
pediatric study in 40 children undergoing cardiac surgery
revealed that urineKIM-1 at 12 h postoperative had anAUCof
0.83 for detection of subsequent AKI [19]. A similar result for
the accuracy of KIM-1 in the prediction of AKI to our study
was obtained in a study which included 252 children (mean
age 11.4 ± 4.8 years) with various primary organ systemic
diagnoses. In this study, AUC for KIM-1 to predict AKI was
0.61 (95% CI 0.48–0.73) [20]. Patients were classified by the
Cr-based pediatric modified RIFLE (pRIFLE), and KIM-1
had a higher AUC for predicting the presence of pRIFLE-
I AKI than for predicting pRIFLE-R AKI. Based on this
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results and results from our study, KIM-1 could serve as AKI
biomarker in more severely-ill children.
The limitations of our study are the small study popu-
lation, and therefore small numbers of patients in groups
with AKI and without AKI, and the absence of data controls.
However, because of the design of the study, formation of a
control group was not necessary. Furthermore, the lack of
data from a dimercaptosuccinic acid (DMSA) scan is not
critical, because the main aim of this study was to investigate
the stability of KIM-1 as a AKI biomarker in a state of
inflammation in children with UTI.
5. Conclusions
Our findings suggest that although uNGAL is suitable for
early diagnosis of UTI, it cannot be used for screening of
the duration of inflammation during UTI or the severity
of the illness. On the other hand, KIM-1 is less sensitive
to the state of inflammation than NGAL and hence more
specific to ischemic kidney injury, accuracy of KIM-1 in
screening of AKI development in children with UTI is not
so good. But for now, it should not be dismissed that KIM-1
is a potential biomarker for AKI in the pediatric population
with UTI, since it is used from a urine sample instead of
blood, and the ongoing development of rapid screening urine
test strips. However, we should consider the implementation
of a comprehensive study that would examine the negative
predictive value of KIM-1 in AKI development during UTI
and developing an algorithm that would greatly facilitate the
work of pediatricians.
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